SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Suven Life Sciences - Quaterly Results

07 May 2022 Evaluate
The total revenue hovered 171.10% to Rs. 42.21 millions for the March 2022 quarter as against Rs. 15.57 millions during the corresponding quarter last year.The Net Loss for the quarter ended March 2022 is Rs. -85.54 millions as compared to Net Loss of Rs. -85.09 millions of corresponding quarter ended March 2021 Operating profit Margin for the quarter ended March 2022 further decreased to -73.54% as compared to -72.21% of corresponding quarter ended March 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 42.21 15.57 171.10 118.44 134.78 -12.12 118.44 134.78 -12.12
Other Income 1.18 13.23 -91.08 53.17 77.54 -31.43 53.17 77.54 -31.43
PBIDT -73.54 -72.21 1.84 -313.26 -227.93 37.44 -313.26 -227.93 37.44
Interest 0.98 1.76 -44.32 5.30 8.15 -34.97 5.30 8.15 -34.97
PBDT -74.52 -73.97 0.74 -318.56 -236.08 34.94 -318.56 -236.08 34.94
Depreciation 11.02 10.66 3.38 43.93 43.46 1.08 43.93 43.46 1.08
PBT -85.54 -84.63 1.08 -362.49 -279.54 29.67 -362.49 -279.54 29.67
TAX 0.00 0.46 0.00 0.00 -53.23 0.00 0.00 -53.23 0.00
Deferred Tax 0.00 0.46 0.00 0.00 -53.23 0.00 0.00 -53.23 0.00
PAT -85.54 -85.09 0.53 -362.49 -226.31 60.17 -362.49 -226.31 60.17
Equity 145.38 127.28 14.22 145.38 127.28 14.22 145.38 127.28 14.22
PBIDTM(%) -174.22 -463.78 -62.43 -264.49 -169.11 56.40 -264.49 -169.11 56.40

Suven Life Sciences Share Price

195.90 -0.10 (-0.05%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×